Now showing items 1-3 of 3

    • Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics 

      Frederick, Dennie T.; Salas Fragomeni, Roberto A.; Schalck, Aislyn; Ferreiro-Neira, Isabel; Hoff, Taylor; Cooper, Zachary A.; Haq, Rizwan; Panka, David J.; Kwong, Lawrence N.; Davies, Michael A.; Cusack, James C.; Flaherty, Keith T.; Fisher, David E.; Mier, James W.; Wargo, Jennifer A.; Sullivan, Ryan J. (Public Library of Science, 2014)
      While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with ...
    • Immunotherapy in the Precision Medicine Era: Melanoma and Beyond 

      Su, Mack Y.; Fisher, David E. (Public Library of Science, 2016)
      In a Perspective, Mack Su and David Fisher discuss the development of immunotherapies for treatment of melanoma and other cancer types.
    • Induction of Histiocytic Sarcoma in Mouse Skeletal Muscle 

      Liu, Jianing; Hettmer, Simone; Milsom, Michael D.; Hofmann, Inga; Hua, Frederic; Miller, Christine; Bronson, Roderick Terry; Wagers, Amy Jo (Public Library of Science, 2012)
      Myeloid sarcomas are extramedullary accumulations of immature myeloid cells that may present with or without evidence of pathologic involvement of the bone marrow or peripheral blood, and often coincide with or precede a ...